Physician profile
Lacey Appachu
NPI 1124850649
$2,563.90
in general payments reported to CMS, 2019-2025
24 companies · $1,803 in 2025
The $1,803 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $761 · 2025: $1,803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,563.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Progenics Pharmaceuticals, INC. | $372.84 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $343.49 | 2024-2025 | Orgovyx, Gemtesa |
| Ferring Pharmaceuticals INC. | $232.99 | 2024-2025 | Adstiladrin |
| Bayer Healthcare Pharmaceuticals INC. | $188.16 | 2025 | |
| Janssen Biotech, INC. | $159.02 | 2024-2025 | Erleada |
| Blue Earth Diagnostics | $151.63 | 2024-2025 | Posluma |
| 180 Medical, INC. | $143.57 | 2024-2025 | Gentlecath, Gentlecath Glide |
| Dendreon Pharmaceuticals LLC | $110.02 | 2024-2025 | Provenge |
| Urogen Pharma, INC. | $94.53 | 2025 | |
| Coloplast Corp | $92.71 | 2024-2025 | |
| Pfizer INC. | $76.88 | 2025 | |
| Novartis Pharmaceuticals Corporation | $68.98 | 2024-2025 | |
| C. R. Bard, INC. & Subsidiaries | $64.80 | 2025 | Bard Urinary Drainage Bag |
| Antares Pharma, INC. | $64.53 | 2024-2025 | Xyosted |
| Teleflex LLC | $56.09 | 2025 | Barrigel, Urolift |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $54.59 | 2025 | Xtandi |
| Merck Sharp & Dohme LLC | $54.31 | 2025 | Keytruda |
| Vertex Pharmaceuticals Incorporated | $46.52 | 2024-2025 | |
| Endo USA, INC. | $46.51 | 2024-2025 | Xiaflex, Aveed |
| Abbvie INC. | $44.37 | 2025 | |
| Myriad Genetic Laboratories, INC. | $42.72 | 2024 | Prolaris |
| Axonics, INC. | $22.93 | 2024 | Axonics |
| Astrazeneca Pharmaceuticals LP | $17.50 | 2025 | |
| Boston Scientific Corporation | $14.21 | 2025 | Ams 700 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lacey Appachu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.